Roche Diagnostics Korea posts record performance

Channel expansion and companion diagnostics growth drive 5th consecutive year of rising sales

Impact of APA-related base effect eliminated… underlying profitability remains stable

Digital adoption and Alzheimer’s diagnostics expected to fuel further growth

Roche Diagnostics, the leader in in vitro diagnostics, has been delivering clear top-line growth every year on the back of its broad portfolio.

Even over the past five years, sales have shown a steady upward trend, and the company is credited with firmly establishing growth momentum through the expansion of companion diagnostics and the successful market penetration of digital solutions.

Channel expansion and companion diagnostics growth… 5 consecutive years of top-line expansion

According to the audit report of Roche Diagnostics Korea, sales in 2025 reached KRW 460.3 billion, up approximately KRW 38.3 billion from KRW 422.0 billion in the previous year.

Looking at revenue over the past 5 years, the company has shown a steady upward trend: ▲KRW 341.3 billion in 2021, ▲ KRW 374.0 billion in 2022, ▲ KRW 394.4 billion in 2023, and ▲ KRW 422.0 billion in 2024.

The expansion of sales and distribution channels is cited as the primary driver of this revenue growth.

Analysts note that as access to testing expanded during the COVID-19 pandemic, the company shifted from a structure centered on large hospitals to one that includes medium-sized hospitals and testing centers, broadening its customer base and increasing the number of equipment installations.

Given the nature of the in vitro diagnostics business, where reagent and consumables sales recur after equipment installation, this channel expansion is highly likely to provide a foundation for mid- to long-term growth.

The expansion of companion diagnostics is also cited as a factor driving revenue growth.

The Roche Group has adopted Personalized Healthcare (PHC) as a core strategy, and the role of companion diagnostics, which identifies patient groups that stand to benefit most from the specific targets of innovative new drugs, has become more important than ever.

As specific biomarker-based therapies continue to increase, demand for pathology and molecular diagnostic testing is rising, and with more therapies gaining reimbursement along with market launch, this is being evaluated as a driver of stable sales growth.

However, the company’s operating profit left something to be desired. While operating profit jumped significantly from KRW 19.1 billion in 2023 to KRW 30.8 billion in 2024, it fell to KRW 18.5 billion last year, returning to the level of two years ago.

Nevertheless, the decline in profitability is interpreted as a result of the base effect from prior price adjustments rather than an actual business slowdown.

Roche Diagnostics Korea has entered into an Advance Pricing Agreement (APA) with its parent company, Roche Diagnostics International Ltd., and has reflected prior-year transfer pricing adjustments through a term test.

In 2024, about KRW 18.3 billion in transfer pricing adjustments covering 2022 through 2024 was deducted from cost of sales, significantly boosting operating profit. In contrast, in 2025, as the term of the APA expired, there was no corresponding reduction in the cost of sales.

As a result, the company’s 2025 operating profit of KRW 18.6 billion is interpreted as a sign of sustained fundamental strength, as it represents profitability generated solely through actual business operations without the benefit of transfer pricing adjustments.

From digital adoption to Alzheimer’s diagnostics… new businesses move into full swing

As Roche Diagnostics Korea continues to strengthen both top-line growth and underlying business quality, the company’s new growth area of building a ‘digital ecosystem’ is also yielding tangible results.

Roche Diagnostics Korea launched a separate Digital Insights business unit and is driving the digital transformation of diagnostic laboratories into Smart Labs, led by NAVIFY, its cloud-based data integration platform.

As a new business area, the digital segment currently accounts for a relatively small portion of total revenue. In particular, the Korean healthcare environment tends to be highly conservative toward adopting new digital systems, with data interoperability relatively low, and institutional support, including reimbursement, is still not fully in place.

Nevertheless, the newly launched Digital Insights Business Unit is reported to have successfully established itself in the market by achieving the key performance indicators (KPIs) set for the Korean market last year.

Muhwan Yun, Head of Digital Insights at Roche Diagnostics Korea, explained, “Healthcare digitalization is now an unavoidable new normal, and we have entered the era of artificial intelligence transformation. NAVIFY is a truly Smart Lab tool that reduces the time healthcare professionals spend on administrative tasks, allowing them to focus solely on patient care.”

The biggest reason the industry is looking positively at Roche Diagnostics Korea’s future is its ‘Blood diagnostic portfolio for Alzheimer’s,’ for which a new approval is strongly anticipated as early as the end of this year.

Recently, Roche’s blood-based biomarker test for Alzheimer’s disease, ‘Elecsys pTau181,’ which Roche developed jointly with Eli Lilly, achieved full approval from the U.S. Food and Drug Administration (FDA).

This is a groundbreaking innovation capable of detecting the accumulation of amyloid plaques and tau proteins at an early stage using just a single drop of blood, without the need for invasive cerebrospinal fluid tests or expensive PET imaging.

If this Alzheimer’s blood diagnostic device secures domestic approval, it is expected to serve as a game-changer that could elevate Roche Diagnostics Korea’s performance next year to a new level in the domestic market, where demand for early dementia diagnosis is surging.